CD69 and neoplasm: Notably, UTMD‐mediated BMP9 delivery increased the expression of the activation marker CD69 in NK cells, restoring the anti‐tumour function of NK cells when administered in combination with the PD‐L1 inhibitor (Figure 7F,G).